Amicoat
Amicoat provides novel antimicrobial technology with broad applications in medical devices and other industries.
Amicoat provides novel antimicrobial technology with broad applications in medical devices and other industries.
Amicoat is a Norwegian biotechnology company established in 2014, specializing in the discovery, development, and commercialization of innovative antimicrobial technology. The company's flagship product has diverse applications across various industries, particularly in the medical devices sector. Amicoat's slogan underscores its commitment to providing groundbreaking antimicrobial solutions that can revolutionize the medical and other relevant industries by enhancing safety and efficacy.
With its primary focus on biotechnology and pharmaceutical industries, Amicoat aims to address the pressing need for advanced antimicrobial solutions. Despite its headquarters' location not being available, the company's potential for growth and innovation in these sectors is substantial.
Although details regarding last investment and the associated investors are currently unavailable, it is evident that Amicoat's pioneering work in the field of antimicrobial technology has caught the attention of potential investors and is likely to attract further investment interest in the future.
There is no investment information
No recent news or press coverage available for Amicoat.
We care about your data, and we'd love to use cookies make your experience better.
